BPH may impact the lifestyles of many younger men1
- More than 9 million men between the ages of 40 and 59 experience BPH symptoms2
BPH is common in men with concomitant conditions1
- 72% of men with erectile dysfunction (ED) also have lower urinary tract symptoms (LUTS)3
- A recent study assessing the prevalence of concomitant diseases in men who sought treatment for ED found BPH was as prevalent as hypertension and diabetes in men with ED4
Men undergoing "watchful waiting" may be living with BPH symptoms unnecessarily
In a study of 446 men categorized as watchful waiters5,6
The disruptions of BPH force many men to change the way they live
 |
Diagnosing BPH |
Important Safety Information
FLOMAX is indicated to treat the signs and symptoms of benign prostatic hyperplasia (BPH). FLOMAX is not indicated to treat hypertension. As with other alpha-adrenergic blocking agents, there is a potential risk of syncope. Patients beginning treatment with FLOMAX should be cautioned to avoid driving or hazardous tasks for 12 hours after their first dose or increase in dose should syncope occur. The most common side effects are dizziness, abnormal ejaculation, and rhinitis.
Caution should be exercised with concomitant administration of warfarin and FLOMAX. In addition, FLOMAX should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. FLOMAX is contraindicated in patients known to be hypersensitive to tamsulosin HCl or any component of FLOMAX.
Before prescribing FLOMAX, please see the full Prescribing Information.
1. Platz EA, Smit E, Curhan GC, Nyberg LM Jr, Giovannucci E. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in US men. Urology. 2002;59:877-883.
2. Decision Resources Patient Base. Data accessed on July 18, 2006.
3. Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "aging male" symptoms? Results of the "Cologne Male Survey." Eur Urol. 2003:44:588-594.
4. Kirby RS. The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology. 2000;56(suppl 5A):3-6.
5. Jiménez-Cruz F. Identifying patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) at risk for progression. Eur Urol Suppl. 2003;2(7):6-12.
6. Dobrovits M, Chaudry A, Anagnostou T, et al. A longitudinal prospective study of men with mild symptoms of BOO treated with watchful waiting over 4 years. Eur Urol Suppl. 2003;2(1):26.
7. Garraway WM, Russell EBAW, Lee RJ, et al. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract. 1993;43:318-321.
